Wisevoter
U.S.

MAIA Biotechnology Advanced Lung Cancer Drug Trials

The company completed enrollment for a Phase 2 trial and reached key recruitment milestones for its Phase 3 study.

Updated on Oct. 7, 2026 in Biotech

Isometric editorial illustration of a laboratory centrifuge rotor holding test tubes, representing clinical drug development.
MAIA Biotechnology has completed enrollment for its Phase 2 clinical trial while advancing patient recruitment for its pivotal Phase 3 study of the lung cancer drug ateganosine. AI Illustration. Upload story photo >

Live Poll

Should the government expedite the approval process for new cancer drug candidates?

MAIA Biotechnology has completed enrollment for Part C of its THIO-101 Phase 2 clinical trial while simultaneously recruiting 65 patients for its pivotal THIO-104 Phase 3 trial. The investigational drug, ateganosine, is a telomere-targeting agent designed to treat non-small cell lung cancer.

Why it matters

Ateganosine aims to provide a vital third-line treatment option for patients who have already progressed following chemotherapy and checkpoint inhibitor therapy. The drug received Fast Track designation from the FDA in July 2025 to accelerate its potential clinical path.

Ateganosine induces telomere-dependent DNA damage to trigger immune responses in patients. The Phase 2 trial reported 90.5% disease control in 150 patients treated with ateganosine in combination with immune checkpoint inhibitors.

The players

MAIA Biotechnology

This is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies.

FDA

The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and approving clinical trial designations in the United States.

The details

The drug works by inducing telomeric DNA modification, which leads to damaged telomeric fragments that activate the patient's innate and adaptive immune systems. Following this approach, the company is focusing the THIO-104 trial on patients who exhausted previous lines of standard treatment.

Timeline

  1. July 2025: FDA granted Fast Track designation for ateganosine.

  2. December 2025: First patient was dosed in the THIO-104 trial.

  3. October 7, 2026: Company announced its latest enrollment milestones.

  4. Year-end 2026: Target date to enroll 100 patients in the THIO-104 trial.

  5. 2027: Planned timeline for an interim analysis of the THIO-104 trial.

The Tech Race

The development of ateganosine reflects the broader shift in oncology toward telomere-targeting agents that trigger systemic immune responses. This approach positions the company against existing checkpoint inhibitor therapies by providing a mechanism to re-engage the immune system in resistant cancers.

Patients and healthcare providers should monitor the trial progress for future availability of this potential third-line therapy. If approved, ateganosine would benefit from five years of marketing exclusivity, potentially impacting the competitive landscape for non-small cell lung cancer treatments.

The takeaway

The progression of ateganosine highlights the importance of targeting telomere DNA damage to overcome drug resistance in advanced cancer. Patients should consult with oncologists about participating in active clinical trials if standard treatments have failed.

What happens next

MAIA Biotechnology aims to reach an enrollment of 100 patients in its THIO-104 trial by the end of 2026, followed by an interim analysis of the trial data scheduled for 2027.

Further reading

Learn more about emerging therapies and studies in the Biotech section.

Live Poll

Should the government expedite the approval process for new cancer drug candidates?